Event │ Discovery on Target
September 16, 2019 – September 19, 2019
Visit us at booth 332!
Kari Wong, PhD, Director, Discovery and Translational Sciences, Metabolon, Inc.
Precision Metabolomics: Understanding the Complexity of NAFLD/NASH
September 17, 2019 at 2:55 PM
Disease drivers including genetics, environmental cues and microbiota drive the development of nonalcoholic-steatohepatitis(NASH). The constellation of factors inciting NASH has spawned a remarkable array of targets. A tool for augmenting the challenges of R&D programs is Metabolon’s Metabolomics platform. By identifying 1000+ metabolites in a single sample across pathways that underly NASH pathogenesis, key insights of target/molecule combinations can be illuminated with this platform. This approach can be applied at any stage of drug development.